ATE283069T1 - Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung - Google Patents

Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Info

Publication number
ATE283069T1
ATE283069T1 AT97936164T AT97936164T ATE283069T1 AT E283069 T1 ATE283069 T1 AT E283069T1 AT 97936164 T AT97936164 T AT 97936164T AT 97936164 T AT97936164 T AT 97936164T AT E283069 T1 ATE283069 T1 AT E283069T1
Authority
AT
Austria
Prior art keywords
melanoma
cell line
immunominant
share
cell lines
Prior art date
Application number
AT97936164T
Other languages
English (en)
Inventor
Drew M Pardoll
Elizabeth M Jaffee
Adam Adler
Suzanne L Topalian
Steven A Rosenberg
Original Assignee
Univ Johns Hopkins Med
Usa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins Med, Usa filed Critical Univ Johns Hopkins Med
Application granted granted Critical
Publication of ATE283069T1 publication Critical patent/ATE283069T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97936164T 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung ATE283069T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2409896P 1996-08-16 1996-08-16
PCT/US1997/012868 WO1998006746A2 (en) 1996-08-16 1997-08-04 Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same

Publications (1)

Publication Number Publication Date
ATE283069T1 true ATE283069T1 (de) 2004-12-15

Family

ID=21818860

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97936164T ATE283069T1 (de) 1996-08-16 1997-08-04 Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung

Country Status (8)

Country Link
US (1) US6187306B1 (de)
EP (1) EP0929318B1 (de)
JP (5) JP2001517206A (de)
AT (1) ATE283069T1 (de)
AU (1) AU3889997A (de)
CA (1) CA2263503C (de)
DE (1) DE69731756T2 (de)
WO (1) WO1998006746A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6277368B1 (en) 1996-07-25 2001-08-21 The Regents Of The University Of California Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine
US5891432A (en) 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
EP1069917A4 (de) * 1998-03-20 2005-02-09 Genzyme Corp Neue komplementierende rezeptor-liganden paare und adoptive immunotherapie die diese verwendet
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
US6316420B1 (en) * 1998-07-28 2001-11-13 Technion Research And Development Foundation Ltd. DNA cytokine vaccines and use of same for protective immunity against multiple sclerosis
GB9827228D0 (en) * 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
DE19905501B4 (de) * 1999-02-10 2005-05-19 MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels
US20030232399A1 (en) * 2000-06-14 2003-12-18 Robertson John Forsyth Russell Cancer detection methods and reagents
US6541250B2 (en) 2000-06-22 2003-04-01 Aventis Pasteur Limited Continuous adherent melanocyte cell line
US20050201993A1 (en) * 2002-10-09 2005-09-15 Link Charles J.Jr. Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase
CN1756568A (zh) * 2002-10-09 2006-04-05 衣阿华中央卫生系统 使用表达α(1,3)－半乳糖基转移酶的同种异型肿瘤细胞的抗肿瘤免疫
GB2395270B (en) * 2002-11-14 2006-08-16 Univ Nottingham Tumour marker proteins and uses thereof
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
GB2426581A (en) * 2005-05-27 2006-11-29 Univ Nottingham Immunoassay methods
SI1889059T1 (sl) 2005-05-27 2009-12-31 Oncimmune Ltd Izboljšani imunotestni postopek
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
CN101632020B (zh) 2006-09-13 2013-11-27 昂西免疫有限公司 改进的免疫测定方法
US7998486B2 (en) 2006-10-25 2011-08-16 Newlink Genetics Corporation Enhanced immunogenicity of tumor associated antigens by addition of alphaGal epitopes
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0725239D0 (en) * 2007-12-24 2008-02-06 Oncimmune Ltd Calibrator for autoantibody assay
EP2492300B1 (de) * 2009-10-23 2018-10-03 Dow Corning Toray Co., Ltd. Neues organopolysiloxan-copolymer
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
CN110520530A (zh) 2016-10-18 2019-11-29 明尼苏达大学董事会 肿瘤浸润性淋巴细胞和治疗方法
KR20240024328A (ko) 2016-11-22 2024-02-23 알로플렉스 바이오테라퓨틱스 동종이형 종양 세포 백신
EP3645021A4 (de) 2017-06-30 2021-04-21 Intima Bioscience, Inc. Adeno-assoziierte virale vektoren zur gentherapie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595653A (en) 1981-06-09 1986-06-17 Lee Biomolecular Research Laboratories, Inc. Process for assaying cellular immunity
US5045320A (en) 1989-03-23 1991-09-03 Medical Biology Institute Large multivalent immunogen
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
CA2091346C (en) 1990-09-14 2007-04-24 Philip Frost Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU677165B2 (en) * 1991-10-04 1997-04-17 Johns Hopkins University School Of Medicine, The The regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
DK0668350T4 (da) * 1994-02-16 2009-02-23 Us Gov Health & Human Serv Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom
EP0756604A1 (de) * 1994-04-22 1997-02-05 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Melanoma antigene
US5759535A (en) * 1994-05-13 1998-06-02 Research Corporation Technologies, Inc. Immunotherapeutic strategies for the treatment of cancer

Also Published As

Publication number Publication date
EP0929318A2 (de) 1999-07-21
WO1998006746A3 (en) 1998-05-07
JP2014012738A (ja) 2014-01-23
AU3889997A (en) 1998-03-06
CA2263503C (en) 2012-04-10
DE69731756T2 (de) 2005-12-15
US6187306B1 (en) 2001-02-13
DE69731756D1 (de) 2004-12-30
JP2008044969A (ja) 2008-02-28
JP2012001548A (ja) 2012-01-05
WO1998006746A2 (en) 1998-02-19
JP2016106137A (ja) 2016-06-16
CA2263503A1 (en) 1998-02-19
JP2001517206A (ja) 2001-10-02
EP0929318B1 (de) 2004-11-24

Similar Documents

Publication Publication Date Title
ATE283069T1 (de) Melanomzellinien, welche immundominante melanomantigene teilen und verfahren zu deren anwendung
DE69737592D1 (de) Mittel gegen juckreiz
IT7920944A0 (it) Metodo, apparato e corpo disupporto di registrazioni per la registrazione ottica di informazioni.
DE69205396D1 (de) Geschäftsformularsätze und Verfahren und Vorrichtung zu deren Herstellung.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
ATE224184T1 (de) Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
DE69333168D1 (de) Vorrichtung und verfahren zur aufnahme eines medizinischen instrumentes
DE69839992D1 (de) Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff
DE68922885D1 (de) Verfahren und Vorrichtung zur Schallbilderzeugung.
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
DE69109213D1 (de) Verfahren und Vorrichtung zur Erzeugung von Röntgenstrahlen.
ITMI932539A0 (it) Procedimento per la terminazione di polimerizzazione in emulsione che non genera nitrosammine
DE68910143D1 (de) Verfahren und Modulation eines optischen Strahlenbündels.
DE3781989D1 (de) Vorrichtung und verfahren zur informationskodierung eines optischen strahles.
FI874419A7 (fi) Laitteisto ja menetelmä kohteen ominaisuuksien tutkimiseen.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
FI901987A0 (fi) Anordning foer blaosformning av en ihaolig kropp.
ES2088128T3 (es) Aminosulfonilureas inhibidoras de acat.
FI800874A7 (fi) Järjestelmä ja menetelmä suurennettujen tai pienennettyjen kuvien muodostamista varten.
DE69100835D1 (de) Apparat zur Erzeugung von Röntgenstrahlen und Verfahren zur Isolierung des Apparatus zur Erzeugung von Röntgenstrahlen.
DE69132575D1 (de) Sampangin-derivate zur verwendung als antimykotische und antimykobakterielle wirkstoffe
DK0538341T3 (da) EHV-4-gycoproteinvaccine.
DE3889903D1 (de) Verfahren zur behandlung der verborgenen linien eines bildes.
FI944294A0 (fi) Menetelmä ja laitteisto hissin toiminnan varmistamMenetelmä ja laitteisto hissin toiminnan varmistamiseksi iseksi
DE69022485D1 (de) Elektro-Schweissmuffe sowie Verfahren und Vorrichtung zu deren Herstellung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties